Methoxypropane
Names
Preferred IUPAC name
Other names
Propane, 1-methoxy- methyl propyl ether Metopryl Neothyl propane, 1-methoxy methyl n-propyl ether
Identifiers
CAS Number
3D model (JSmol )
ChemSpider
ECHA InfoCard
100.008.327
EC Number
RTECS number
UNII
UN number
2612
InChI=1S/C4H10O/c1-3-4-5-2/h3-4H2,1-2H3
Y Key: VNKYTQGIUYNRMY-UHFFFAOYSA-N
Y InChI=1/C4H10O/c1-3-4-5-2/h3-4H2,1-2H3
Properties
Chemical formula
C4 H10 O
Molar mass
74.12
Density
0.7356 g/cm3
Boiling point
38.8 °C (101.8 °F; 311.9 K)
Solubility in water
30.5 g/L
Refractive index (n D )
1.35837 (14.3 °C)
Viscosity
0.3064 cP (0.3 °C)
Pharmacology
Routes of administration
inhalation
Hazards
NFPA 704 (fire diamond)
Flash point
< −20 °C (−4 °F; 253 K)
Explosive limits
1.9-11.8
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N (what is Y N ?)
Infobox references
Chemical compound
Methoxypropane , or methyl propyl ether , is an ether once used as a general anaesthetic .[1] It is a clear colorless flammable liquid with a boiling point of 38.8 °C.[2]
Marketed under the trade names Metopryl and Neothyl , methoxypropane was used as an alternative to diethyl ether because of its greater potency. Its use as an anaesthetic has since been supplanted by modern halogenated ethers which are much less flammable.
References [ ]
^ White, Mary Louise T.; Shane, Sylvan M.; Krantz, John C., Jr. "Anesthesia. XXI. Propyl methyl ether as an inhalation anesthetic in man", Anesthesiology , (1946), 7, 663-7.
^ Merck Index , 11th edition, 6031 .
General anesthetics (N01A )
Inhalational
Chloroethane (ethyl chloride) ‡
Chloroform ‡
Cyclopropane ‡
Desflurane
Diethyl ether ‡
Enflurane
Ethylene ‡
Fluroxene ‡
Halothane #
Isoflurane #
Methoxyflurane
Methoxypropane ‡
Nitrous oxide #
Sevoflurane
Trichloroethylene ‡
Vinyl ether ‡
Xenon
Injection
Phenols Barbiturates Opioids
Morphine #
Oxycodone
Anileridine ‡
Embutramide ‡
Fentanyl #
Alfentanil
Phenoperidine
Remifentanil ÷
Sufentanil
Arylcyclohexylamines Neuroactive steroids Others
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III
GABA A receptor positive modulatorsAlcohols
Butanol
Chloralodol
Chlorobutanol (cloretone)
Ethanol (alcohol) (alcoholic drink )
Ethchlorvynol
Isobutanol
Isopropanol
Menthol
Methanol
Methylpentynol
Pentanol
Petrichloral
Propanol
tert -Butanol (2M2P)
tert -Pentanol (2M2B)
Tribromoethanol
Trichloroethanol
Triclofos
Trifluoroethanol
Barbiturates Benzodiazepines Carbamates Flavonoids
Ampelopsin (dihydromyricetin)
Apigenin
Baicalein
Baicalin
Catechin
EGC
EGCG
Hispidulin
Luteolin
Skullcap constituents (e.g., baicalin )
Wogonin
Imidazoles Kava constituents
Desmethoxyyangonin
Kavain
Methysticin
Yangonin
Monoureides Neuroactive steroids Nonbenzodiazepines Phenols
Fospropofol
Propofol
Thymol
Piperidinediones Pyrazolopyridines Quinazolinones Volatiles /gases Others/unsorted
3-Hydroxybutanal
Avermectins (e.g., ivermectin )
Bromide compounds (e.g., lithium bromide , potassium bromide , sodium bromide )
Carbamazepine
Chloralose
Chlormezanone
Clomethiazole
DEABL
Dihydroergolines (e.g., dihydroergocryptine , , dihydroergotamine , ergoloid (dihydroergotoxine) )
Efavirenz
Etazepine
Etifoxine
Fenamates (e.g., flufenamic acid , mefenamic acid , niflumic acid , tolfenamic acid )
Fluoxetine
Flupirtine
Hopantenic acid
Lanthanum
Lavender oil
Lignans (e.g., 4-O-methylhonokiol , honokiol , magnolol , obovatol )
Loreclezole
Menthyl isovalerate (validolum)
Monastrol
Niacin
Niacinamide
Org 25,435
Phenytoin
Propanidid
Retigabine (ezogabine)
Safranal
Seproxetine
Stiripentol
(e.g., sulfonmethane (sulfonal) , tetronal , trional )
Terpenoids (e.g., borneol )
Topiramate
Valerian constituents (e.g., isovaleric acid , isovaleramide , valerenic acid , )
Unsorted benzodiazepine site positive modulators: α-Pinene
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators